Navigation Links
BioMed Realty Trust Reports First Quarter 2008 Financial Results
Date:4/30/2008

124

We present funds from operations, or FFO, available to common shares and partnership and LTIP units because we consider it an important supplemental measure of our operating performance and believe it is frequently used by securities analysts, investors and other interested parties in the evaluation of REITs, many of which present FFO when reporting their results. FFO is intended to exclude GAAP historical cost depreciation and amortization of real estate and related assets, which assumes that the value of real estate assets diminishes ratably over time. Historically, however, real estate values have risen or fallen with market conditions. Because FFO excludes depreciation and amortization unique to real estate, gains and losses from property dispositions and extraordinary items, it provides a performance measure that, when compared year over year, reflects the impact to operations from trends in occupancy rates, rental rates, operating costs, development activities and interest costs, providing perspective not immediately apparent from net income. We compute FFO in accordance with standards established by the Board of Governors of the National Association of Real Estate Investment Trusts, or NAREIT, in its March 1995 White Paper (as amended in November 1999 and April 2002). As defined by NAREIT, FFO represents net income (computed in accordance with GAAP), excluding gains (or losses) from sales of property, plus real estate related depreciation and amortization (excluding amortization of loan origination costs) and after adjustments for unconsolidated partnerships and joint ventures. Our computation may differ from the methodology for calculating FFO utilized by other equity REITs and, accordingly, may not be comparable to such other REITs. Further, FFO does not represent amounts available for management's discretionary use because of needed capital replacement or expansion, debt service obligations, or other commitments and uncertainties. FFO should no
'/>"/>

SOURCE BioMed Realty Trust, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. BioMed Realty Trust to Report 2008 First Quarter Results
2. The BBVA Foundation awards its 2007 Biomedicine Chairs
3. HHS Names First Director of the Biomedical Advanced Research Development Authority
4. BioMed Realty Trust Announces 90,000 Square Foot Lease at Pacific Research Center
5. DeBakey Awards to Recognize Excellence in Biomedical Research Journalism
6. LA BioMed to honor 3 of its legendary
7. Response Biomedical Corporation Reports 2007 Financial Results
8. Response Biomedical Corporation Moves to New Facility
9. Response Biomedical Corp. - Year End 2007 Earnings Webcast and Conference Call - March 31, 2008
10. LA BioMed researcher says unexpected increase in cancer risk found
11. LA BioMed study finds hormone therapy increases frequency of abnormal mammograms, breast biopsies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... , ... July 27, 2015 , ... ... Step One, **FDAnews Webinar**, Aug. 13, 2015 — 1:30 p.m. – 3:00 p.m. ... of the first things FDA investigators will look at during an inspection. ...
(Date:7/27/2015)... ... July 27, 2015 , ... On July 14, 2015, Harper’s Bazaar ... Issues,” describes common skin issues such as stretch marks , fine lines ... treat them. The treatment options listed include lasers, ultrasound, radio frequency, Botox, and dermal ...
(Date:7/27/2015)... ... July 27, 2015 , ... North Central Surgical Center Hospital will be holding ... all those prospective joint-replacement patients, along with their friends and family members, to attend. ... classes (Aug 6, Sept 8 [Tue due to Labor Day], Oct 5, Nov 2, ...
(Date:7/27/2015)... , ... July 27, 2015 , ... David Gilmour ... He will be performing for one additional night at each of his original four ... DAVID-GILMOUR-2016 for added savings. , David Gilmour’s 2016 North America tour dates: , Thursday, ...
(Date:7/27/2015)... ... July 27, 2015 , ... In an ongoing ... to its options. Already an industry leader because of its use of ... for the latest successful trends in helping people to overcome addiction and live ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 2Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 3Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 4Health News:The Latest Treatment Options for Seven Common Skin Issues 2Health News:North Central Surgical Center Hospital to Hold Joint Wellness Classes 2Health News:Cheap David Gilmour Tickets at Madison Square Garden (MSG), Air Canada Center, United Center and Hollywood Bowl: Additional Dates for David Gilmour Go On Sale Today 2Health News:Hiking Adds Benefits to Recovery at Serenity Palms 2Health News:Hiking Adds Benefits to Recovery at Serenity Palms 3
... Most of the 28 million Americans living with untreated ... corrective action could result in the brain actually "forgetting" how ... , Dr. Beyer is senior vice president of HearUSA (Amex: ... hearing aids companies. , "When the brain is insufficiently stimulated ...
... Fla., Oct. 19 Blue Cross and ... statewide Medicare Advantage Regional PPO plan called BlueMedicare Regional ... offerings for Florida,s Medicare eligibles. The BlueMedicare Regional PPO ... Private Fee-for-Service, Part D and Medicare Supplement plans. , ...
... ... the world,s leading manufacturer and distributor of health testing stations and automated blood pressure ... with UnitedHealth Group,s Passport to Health and Well Being at the 2009 AARP Vegas@50+ ... ...
... ... Biodiagnostics, Inc., today announced that the U.S. Food and Drug Administration ... 15 monoclonal antibodies in its proprietary line of transfusion diagnostics. ... and hospitals to type and screen blood. Quotient Biodiagnostics was formed ...
... CITY, Kan., Oct. 19 Premier Plastic Surgery of Kansas City, ... has redesigned its extensive website to include a separate section ... and a Plastic Surgery Blog that features breaking news on ... Society for Aesthetic Plastic Surgery, cosmetic surgery for males increased ...
... and men have opposing views on many topics, and it ... pain. According to a new survey of women and men ... leading independent health information source for women, women are more ... have a higher tolerance for pain (76% versus 32%, respectively)(1).In ...
Cached Medicine News:Health News:If Hearing Loss is Not Treated, Brain Can 'Forget' How to Hear and Understand Speech 2Health News:Blue Cross and Blue Shield of Florida Now Offers More Choices to Florida's Seniors 2Health News:Blue Cross and Blue Shield of Florida Now Offers More Choices to Florida's Seniors 3Health News:Lifeclinic to Engage People Over 50 in Utilizing Technology and Wellness at AARP 2009 Event and Expo 2Health News:Lifeclinic to Engage People Over 50 in Utilizing Technology and Wellness at AARP 2009 Event and Expo 3Health News:Quotient Biodiagnostics Receives U.S. Food & Drug Administration Clearance to Enter U.S. Transfusion Diagnostics Market 2Health News:Quotient Biodiagnostics Receives U.S. Food & Drug Administration Clearance to Enter U.S. Transfusion Diagnostics Market 3Health News:Premier Plastic Surgery of Kansas City's Extended Website Provides Latest Information on Male and Female Cosmetic Surgery 2Health News:Premier Plastic Surgery of Kansas City's Extended Website Provides Latest Information on Male and Female Cosmetic Surgery 3Health News:Premier Plastic Surgery of Kansas City's Extended Website Provides Latest Information on Male and Female Cosmetic Surgery 4Health News:Women and Men Face Off: Who Can Stand the Pain? 2Health News:Women and Men Face Off: Who Can Stand the Pain? 3
(Date:7/27/2015)...  Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is ... the securities of AMAG Pharmaceuticals Inc. ("AMAG" or ... advised to contact Peretz Bronstein or ... at info@bgandg.com or 212-697-6484. ... its officers and/or directors have violated Sections 10(b) ...
(Date:7/27/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4rvprn/ddimer_testing ) ... Testing Market - Global Industry Analysis, Size, Share, ... report to their offering. ... one of the fastest growing markets globally. This ... health care awareness, preference of the people for ...
(Date:7/27/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/65t478/gprotein_coupled ... "G-Protein Coupled Receptors Market: Global Industry Analysis, Size, ... report to their offering. ... on of assay type, therapeutic area, and geography. ... been categorized into six major segments: cAMP assays, ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals Inc. 2D-dimer Testing Market - Global Industry Analysis 2015 2D-dimer Testing Market - Global Industry Analysis 2015 3G-Protein Coupled Receptors Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022 2
... Transplant Patients Represents First, Pivotal Study on a New Antiviral CMV Therapy in Stem Cell ... Over a Decade ... ... 29 ViroPharma Incorporated,(Nasdaq: VPHM ) today announced that it completed enrollment in its pivotal,Phase ...
... be Presented at ASCO Shows Survival Benefit in Complete ... Partial Responders Compared with Chemotherapy Alone, BERKELEY ... GNTA) announced the results of long-term,followup from a Phase ... sodium) Injection, in patients with chronic,lymphocytic leukemia (CLL). With ...
Cached Medicine Technology:ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 2ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 3ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 4ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 5ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 6Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders 2Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders 3Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders 4
Bone Curette, 160 mm...
Bone Currettes...
London Endocervical Curette is a stainless-steel curette for obtaining endocervical samples with minimal effort....
...
Medicine Products: